Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$5.84 +1.6%	$4.26	$3.21 ▼ $7.18	$1.41B	0.68	4.79 million shs	3.62 million shs
CRSP CRISPR Therapeutics	$58.82 +2.6%	$52.73	$30.04 ▼ $71.13	$5.35B	1.8	2.62 million shs	4.84 million shs
MRUS Merus	$66.94 -0.2%	$58.44	$33.19 ▼ $67.59	$5.06B	1.09	880,846 shs	553,346 shs
VKTX Viking Therapeutics	$40.24 -2.5%	$30.59	$18.92 ▼ $81.73	$4.52B	0.67	4.16 million shs	5.84 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+2.68%	+10.58%	+24.73%	+70.12%	-0.86%
CRSP CRISPR Therapeutics	+2.24%	+2.71%	+2.56%	+59.37%	+20.00%
MRUS Merus	+5.21%	+2.36%	+20.62%	+67.39%	+31.29%
VKTX Viking Therapeutics	+3.54%	+29.45%	+30.48%	+50.62%	-26.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.4238 of 5 stars	3.5	2.0	4.4	3.8	2.5	0.6
CRSP CRISPR Therapeutics	2.9192 of 5 stars	3.3	2.0	0.0	3.2	3.3	0.6
MRUS Merus	2.7462 of 5 stars	3.5	4.0	0.0	1.8	2.5	0.0
VKTX Viking Therapeutics	4.0952 of 5 stars	3.5	1.0	4.7	3.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$11.50	96.92% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	21.73% Upside
MRUS Merus	3.09	Buy	$88.50	32.21% Upside
VKTX Viking Therapeutics	3.00	Buy	$86.92	116.01% Upside

Current Analyst Ratings Breakdown

Latest ARDX, CRSP, MRUS, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/24/2025	VKTX Viking Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$125.00 ➝ $122.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	4.22	N/A	N/A	$0.58 per share	10.07
CRSP CRISPR Therapeutics	$37.31M	143.38	N/A	N/A	$18.81 per share	3.13
MRUS Merus	$36.13M	140.12	N/A	N/A	$11.13 per share	6.01
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.23	N/A	18.84	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	10/30/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest ARDX, CRSP, MRUS, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.44	4.30	4.03
CRSP CRISPR Therapeutics	N/A	16.61	16.61
MRUS Merus	N/A	8.39	8.39
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CRSP CRISPR Therapeutics	69.20%
MRUS Merus	96.14%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
CRSP CRISPR Therapeutics	4.30%
MRUS Merus	3.70%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
MRUS Merus	37	75.63 million	72.84 million	Optionable
VKTX Viking Therapeutics	20	112.44 million	107.84 million	Optionable

ARDX, CRSP, MRUS, and VKTX Headlines

Recent News About These Companies

The 3 Things That Matter for Viking Therapeutics Now

August 13 at 4:10 AM | fool.com

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

August 12 at 4:16 PM | msn.com

Connor Clark & Lunn Investment Management Ltd. Purchases 222,293 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 12 at 5:18 AM | marketbeat.com

Truist Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

August 11 at 8:40 PM | theglobeandmail.com

Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735

August 11 at 8:40 PM | finance.yahoo.com

New Age Alpha Advisors LLC Buys New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 9, 2025 | marketbeat.com

Raiffeisen Bank International AG Buys 13,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 6, 2025 | marketbeat.com

Harbour Investments Inc. Boosts Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 6, 2025 | marketbeat.com

Cetera Investment Advisers Raises Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 8,519 Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 5, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?

August 4, 2025 | zacks.com

NJ State Employees Deferred Compensation Plan Buys 10,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 4, 2025 | marketbeat.com

2 Beaten-Down Stocks With Incredible Upside Potential

August 3, 2025 | fool.com

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts

August 3, 2025 | fool.com

Victory Capital Management Inc. Has $317,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 3, 2025 | marketbeat.com

Short Interest in Viking Therapeutics, Inc. (NASDAQ:VKTX) Expands By 88,996.6%

August 2, 2025 | marketbeat.com

Is Viking Therapeutics the Next Big Biotech Bet?

August 1, 2025 | fool.com

Allianz Asset Management GmbH Sells 35,986 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

August 1, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial

July 31, 2025 | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial

July 31, 2025 | insidermonkey.com

TCW Group Inc. Boosts Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, CRSP, MRUS, and VKTX Company Descriptions

Ardelyx NASDAQ:ARDX

$5.84 +0.09 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$5.82 -0.02 (-0.34%)

As of 04:20 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$58.82 +1.49 (+2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$58.77 -0.05 (-0.08%)

As of 04:21 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Merus NASDAQ:MRUS

$66.94 -0.15 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$66.92 -0.02 (-0.02%)

As of 04:18 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Viking Therapeutics NASDAQ:VKTX

$40.24 -1.03 (-2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$39.92 -0.33 (-0.81%)

As of 04:20 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time